RT Journal Article
T1 Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study.
A1 Martín, Ernesto
A1 López-Aguilera, José
A1 González-Manzanares, Rafael
A1 Anguita, Manuel
A1 Gutiérrez, Guillermo
A1 Luque, Aurora
A1 Paredes, Nick
A1 Oneto, Jesús
A1 Perea, Jorge
A1 Castillo, Juan Carlos
K1 N-terminal pro-B-type natriuretic peptide
K1 canagliflozin
K1 heart failure
K1 readmissions
K1 sodium glucose co-transporter 2 inhibitor
AB Heart failure (HF) is one of the mayor contributors to cardiovascular morbidity and mortality in patients with diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated to reduce the risk of hospitalization for HF in patients with type 2 diabetes mellitus (T2D). We aimed to assess the risk for re-hospitalization in a cohort of patients hospitalized for HF according to whether or not they received canagliflozin at discharge, as well as changes in N-terminal pro-B-type natriuretic peptide (NT-ProBNP) concentration during follow-up. We conducted a retrospective longitudinal study at a tertiary centre including 102 consecutive T2D patients discharged for acute HF without contraindication for SGLT2 inhibitors. We compared adverse clinical events (HF rehospitalization and cardiovascular death) and NT-ProBNP changes according to canagliflozin prescription at discharge. Among the 102 patients included, 45 patients (44.1%) were prescribed canagliflozin and the remaining 57 (55.9%) were not prescribed any SGLT2 inhibitors (control group). After a median follow-up of 22 months, 45 patients (44.1%) were hospitalized for HF. Most of the rehospitalizations occurred during the first year (37.3%). HF readmission at first year occurred in 10 patients (22.2%) in the canagliflozin group and 29 patients (49.1%) in the control group (hazard ratio (HR): 0.45; 95% confidence interval (CI): 0.21-0.96; p  Canagliflozin therapy at discharge was associated with a lower risk of readmission for HF and a reduction in NT-ProBNP concentration in patients with diabetes after hospitalization for HF.
SN 2077-0383
YR 2021
FD 2021-02-01
LK https://hdl.handle.net/10668/28309
UL https://hdl.handle.net/10668/28309
LA en
DS RISalud
RD Apr 11, 2025